PHILIP-MORRIS-INTL
21.1.2020 10:05:13 CET | Business Wire | Press release
As it continues to advocate for greater transparency, objective examination of the science and open debate in creating the right regulation for smoke-free alternatives, Philip Morris International Inc. (PMI) (NYSE:PM) today released a new white paper titled, “Unsmoke Your Mind: Pragmatic Answers to Tough Questions for a Smoke-Free Future” at a press conference in Davos. Based on an independent survey—commissioned by PMI and conducted by Povaddo among 17,251 adults aged 21-74 across 14 countries—the paper examines public opinions of the regulatory, scientific and corporate landscape as PMI focuses on advancing smoke-free products to replace cigarettes as soon as possible.
The white paper shows a keen public appetite for open science and facts-driven policies regarding smoke-free alternatives to cigarettes. Nearly 9 in 10 respondents (87 percent) agreed that “when developing regulations, governments, regulators and public health bodies should consider the current science relating to e-cigarettes and heat-not-burn tobacco products.” Further underscoring support for scientific substantiation in this category is the fact that 89 percent of respondents agreed that “before introducing e-cigarettes and heat-not-burn tobacco products to consumers, manufacturers must conduct robust scientific assessments on their products.”
“Smoke-free alternatives offer a commonsense approach to public health,” said Jacek Olczak, chief operating officer at PMI. “In a time when trust in governments and organizations is at an all-time low, it is essential to base decision-making on science and facts. For PMI, this research reinforces the importance of transparency in sharing the science behind our smoke-free products, making it open for all, be that governments, regulators, scientists, academics or the general public.”
While it is best to quit tobacco and nicotine altogether or never to start using them, the reality is that there are millions of adult smokers who would otherwise continue smoking in the absence of a better alternative. Science and technology have now created these better alternatives, and these men and women should have access to them. Denying them access to these science-based better products means they will continue to smoke.
As smoke-free alternatives are increasingly in the headlines, the Unsmoke Your Mind white paper explores challenging questions the public has about the role of these products today, specifically addressing the following:
- We & Me: Do societies at large really care about smokers?
- Science Illuminates, Science Blinds: Do consumers take scientific evidence seriously or do they disregard “science” as just another marketing trick?
- The Age of Mistrust: How does (mis)trust affect attitudes toward smoke-free alternatives?
- The Promise and the Threat of What’s New: How can we be confident innovations will be better than what they replace?
- Big Isn’t Always Bad: Are there any serious alternatives to “big” in a world of 7.8 billion people?
To read the “Unsmoke Your Mind: Pragmatic Answers to Tough Questions for a Smoke-Free World” paper, visit www.pmi.com/UYMwhitepaper .
Survey Methodology
PMI commissioned Povaddo LLC to conduct an online survey among 17,251 men and women aged 21-74 in 14 countries: Argentina, Australia, Brazil, Germany, Hong Kong, Israel, Italy, Japan, Mexico, the Netherlands, Norway, Russia, the United Kingdom and the United States. The survey was fielded from December 4-19, 2019 in respondents’ native languages. The study carries an overall margin of error of +/- 0.75% at the 95% confidence interval.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. PMI ships a version of its smoke-free
devices and consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com
and www.pmiscience.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200121005451/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
